课题基金 / 基金详情

miR-126-3p/ITGA6信号轴调控扩张型心肌病生物学功能和左心室功能的作用及机制

批准号:
82071950
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
刘琳
依托单位:
学科分类:
超声医学
结题年份:
2024
批准年份:
2020
项目状态:
已结题
项目参与者:
刘琳

项目摘要

结项摘要

刘琳的其他基金

相似基金

相关文献

中文摘要
扩张型心肌病(DCM)是心力衰竭和心源性猝死常见病因,但发病机制尚不明确。前期研究发现,DCM患者血浆中miR-126-3p水平明显降低,相关性分析显示miR-126-3p低表达与DCM患者左心室功能降低有关。生物信息学预测发现,miR-126-3p与整合素α6(ITGA6)的3’UTR区存在结合位点。KEGG分析ITGA6位于PI3K/AKT信号通路上游,与细胞增殖、凋亡及纤维化有关。推测DCM低表达的miR-126-3p可能靶向促进ITGA6表达,调控心肌细胞和左心室功能。本项目拟通过实验,明确DCM患者血浆中miR-126-3p表达与左心室功能的相关性;明确miR-126-3p调控ITGA6对心肌细胞生物学功能及心肌纤维化影响的机制;构建DCM大鼠模型,明确体内miR-126-3p调控ITGA6对DCM左心室功能影响的机制,为阐明DCM发病机制提供新思路,为DCM治疗提供新靶点。
英文摘要
Dilated cardiomyopathy (DCM) is a heart disease characterized by left ventricular dilation with systoli dysfunction. DCM is a common cause of human heart failure and sudden cardiac death, and its pathological mechanism is still unclear. Recent studies have shown that miRNAs are kind of novel non-invasive biomarker of cardiovascular disease, which can play an important role as a clinical indicator and therapeutic target in the etiology of DCM. According to our previous study, high throughput miRNAs microarray found that the plasma level of miR-126-3p was significantly decreased in patients with DCM, which was associated with the decreased left ventricular function. In addition, it was predicted by bioinformatics that miR-126-3p had binding sites in the 3’UTR region of Integrin α6 (ITGA6). KEGG analysis shows that ITGA6 is one of upstream molecules of the PI3K/AKT signaling pathway, which is related to cell proliferation and apoptosis cycle and fibrosis. Thus, it is speculated that the low expression of miR-126-3p in DCM may target ITGA6 and promote its expression to regulate the functions of cardiomyocytes and left ventricle. In vivo and in vitro experiments were carried out in this project to clarify the correlation between the expression of miR-126-3p in plasma of DCM patients and left ventricular function and explore the biological function of cardiomyocytes and myocardial fibrosis of miR-126-3p and its mechanism and investigate the effects of miR-126-3p by regulation of ITGA6 on DCM left ventricular cardiac function in vivo and its mechanism through the establishment of DCM rat models. This study will provide a new idea to elucidate the pathogenesis of DCM and a novel target and direction for the treatment of DCM.
扩张型心肌病(Dilated cardiomyopathy,DCM)是导致心力衰竭和心源性猝死的重要原因之一,但其发病机制尚不明确。近年来,循环miRNA作为非侵入性且可获取的生物标志物,已被广泛关注,并在多种心脏疾病的早期诊断中表现出潜力。然而,与DCM相关的循环miRNA(DACMs)及其在疾病机制中的作用未得到充分探索。本研究通过对比健康人和DCM患者的血清进行miRNA测序和定量聚合酶链反应(qPCR)验证,发现四种循环miRNA(miR-26a-5p、miR-30c-5p、miR-126-5p和miR-126-3p)在DCM患者中显著下调。进一步分析表明,在临床研究方面这些miRNA在循环血液和心脏组织中的表达水平具有显著的相关性,且其联合具有较高的诊断价值。在机制研究方面,FOXO3被预测为这些DACMs的共同靶点,并通过细胞实验验证了除miR-26a-5p外,其他三种miRNA能够显著抑制心肌细胞中的FOXO3表达。进一步研究表明,通过AAV9载体递送miR-30c-5p、miR-126-5p和miR-126-3p至小鼠心肌,或通过心肌特异性敲除FOXO3(Myh6-CreERT2,FOXO3 flox+/+)小鼠模型,显著减轻了DCM进展相关的心肌细胞凋亡和自噬现象,表明DACMs通过调控FOXO3,发挥心脏保护作用。此外,研究还发现竞争性干扰DACMs与FOXO3之间的相互作用,可以削弱DACMs对心肌细胞的保护作用。进一步的研究表明,循环miRNA-FOXO3轴在DCM中的心肌细胞凋亡和过度自噬的调控中起着关键作用,提示该信号轴可能是DCM的潜在治疗靶点。综上所述,本研究揭示了四种循环miRNA(miR-26a-5p、miR-30c-5p、miR-126-5p和miR-126-3p)与扩张型心肌病相关,并深入验证了它们通过调控FOXO3在DCM发病机制中的作用。研究发现,循环心脏miRNA-FOXO3轴在DCM的心肌细胞凋亡和过度自噬过程中起着关键作用。该发现为DCM的非侵入性诊断提供了新的血清学线索,为揭示DCM的发病机制和寻找潜在的治疗靶点提供了重要的理论依据。
超声心动图结合染色体核型及单核苷酸多态性对胎儿单心室的研究
  • 批准号:
    81401419
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2014
  • 负责人:
    刘琳
  • 依托单位:
国内基金
海外基金